Loading company…
Phrontline Biopharma develops antibody-drug conjugates for cancer treatment.
Founded in 2022 and based in Shanghai, Phrontline Biopharma develops antibody-drug conjugates for cancer. Its technology platforms include SynTume and Two By Two ADC, focused on dual targeting and payloads. In November 2025, the company raised USD 60 million in Pre-series A funding led by Lapam Capital, with Decheng Capital and other investors participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in